These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 36534936)

  • 21. Targets in MPNs and potential therapeutics.
    Levy G; Mambet C; Pecquet C; Bailly S; Havelange V; Diaconu CC; Constantinescu SN
    Int Rev Cell Mol Biol; 2022; 366():41-81. PubMed ID: 35153006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [What's new in myeloproliferative neoplasia?].
    Schmidt S; Wolf D
    Dtsch Med Wochenschr; 2022 Mar; 147(6):306-311. PubMed ID: 35291035
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Myeloproliferative neoplasia: a review of clinical criteria and treatment.
    Koopmans SM; van Marion AM; Schouten HC
    Neth J Med; 2012 May; 70(4):159-67. PubMed ID: 22641623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms.
    Gurska LM; Okabe R; Schurer A; Tong MM; Soto M; Choi D; Ames K; Glushakow-Smith S; Montoya A; Tein E; Miles LA; Cheng H; Hankey-Giblin P; Levine RL; Goel S; Halmos B; Gritsman K
    Clin Cancer Res; 2023 Mar; 29(5):943-956. PubMed ID: 36537918
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms.
    Quintás-Cardama A; Verstovsek S
    Cancer; 2012 Feb; 118(4):870-7. PubMed ID: 21766300
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities.
    Coltro G; Loscocco GG; Vannucchi AM
    Int Rev Cell Mol Biol; 2021; 365():1-69. PubMed ID: 34756241
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases.
    Duminuco A; Torre E; Palumbo GA; Harrison C
    Curr Hematol Malig Rep; 2023 Oct; 18(5):176-189. PubMed ID: 37395943
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H; Spivak JL
    Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disease modifying agents of myeloproliferative neoplasms: a review.
    Lee SE
    Blood Res; 2021 Apr; 56(S1):S26-S33. PubMed ID: 33935032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Top advances of the year: Myeloproliferative neoplasms.
    Bhave RR; Mesa R; Grunwald MR
    Cancer; 2023 Dec; 129(23):3685-3691. PubMed ID: 37768996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation.
    Pandey G; Kuykendall AT; Reuther GW
    Blood Cancer J; 2022 Jan; 12(1):13. PubMed ID: 35082276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms.
    Berdeja J; Palandri F; Baer MR; Quick D; Kiladjian JJ; Martinelli G; Verma A; Hamid O; Walgren R; Pitou C; Li PL; Gerds AT
    Leuk Res; 2018 Aug; 71():82-88. PubMed ID: 30025280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms.
    Bose P; Verstovsek S
    Expert Opin Investig Drugs; 2016 Dec; 25(12):1393-1403. PubMed ID: 27756180
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The promise of Janus kinase inhibitors in the treatment of hematological malignancies.
    Senkevitch E; Durum S
    Cytokine; 2017 Oct; 98():33-41. PubMed ID: 28277287
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management.
    Bose P; Verstovsek S
    J Natl Compr Canc Netw; 2016 Dec; 14(12):1613-1624. PubMed ID: 27956543
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence for Janus kinase (JAK) inhibitors for the prevention of major morbid events in patients with myeloproliferative neoplasms (MPNs).
    Pemmaraju N; Mesa R
    Hematology Am Soc Hematol Educ Program; 2015; 2015():649-51. PubMed ID: 26637784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-acting interferon: pioneering disease modification of myeloproliferative neoplasms.
    Yoon SY; Kim SY
    Korean J Intern Med; 2023 Nov; 38(6):810-817. PubMed ID: 37939664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Individualizing Care for Patients With Myeloproliferative Neoplasms: Integrating Genetics, Evolving Therapies, and Patient-Specific Disease Burden.
    Mesa RA; Passamonti F
    Am Soc Clin Oncol Educ Book; 2016; 35():e324-35. PubMed ID: 27249739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans.
    Marubayashi S; Koppikar P; Taldone T; Abdel-Wahab O; West N; Bhagwat N; Caldas-Lopes E; Ross KN; Gönen M; Gozman A; Ahn JH; Rodina A; Ouerfelli O; Yang G; Hedvat C; Bradner JE; Chiosis G; Levine RL
    J Clin Invest; 2010 Oct; 120(10):3578-93. PubMed ID: 20852385
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical application of gene mutation information in myeloproliferative neoplasms].
    Takenaka K
    Rinsho Ketsueki; 2019; 60(6):610-618. PubMed ID: 31281152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.